New Research: MOTS-C Suppresses Cardiac and Systemic Inflammasome Activity in a Diabetic Rat Model

MOTS-C’s research reputation has mostly been built around AMPK activation and metabolic signaling — its identity as a mitochondrial “exercise mimetic” that shows up in glucose-handling studies. A new study from researchers at the University of Auckland, published in Experimental Physiology, extends that picture into a different system entirely: cardiac and systemic inflammation in a rodent model of type 2 diabetes. The findings point to MOTS-C interacting with the NLRP3 inflammasome, a pathway with no direct precedent in the peptide’s prior AMPK-centered literature.

The study design

Type 2 diabetes is associated with chronic low-grade inflammation that contributes over time to diabetic cardiomyopathy, and the NLRP3 inflammasome — a multiprotein complex that activates inflammatory cytokines like IL-1β and IL-18 — is a well-studied driver of that process. The research group used a rat model combining a high-fat diet with streptozotocin, a compound that damages insulin-producing cells, to produce a type 2 diabetes phenotype. Animals then received MOTS-C treatment, after which the researchers measured fasting blood glucose, circulating C-reactive protein (CRP), a panel of plasma cytokines, and — via immunohistochemistry of left ventricular heart tissue — the levels of three inflammasome-pathway markers: NLRP3 itself, the adaptor protein ASC, and cleaved caspase-1.

What they found

MOTS-C-treated animals showed significantly lower fasting blood glucose and circulating CRP than untreated diabetic controls, consistent with the peptide’s established metabolic profile. The cytokine picture was more selective than a blanket anti-inflammatory effect: MOTS-C shifted the balance of specific plasma cytokines, including changes in IL-10 and IL-1β, rather than suppressing inflammatory signaling uniformly. In heart tissue specifically, MOTS-C-treated animals had visibly lower levels of NLRP3, ASC, and cleaved caspase-1 — the core components that make up an active inflammasome complex — indicating reduced inflammasome assembly in the left ventricle. The researchers also found that IL-18 and IL-1β levels correlated with other markers of metabolic strain, including LDL cholesterol and uric acid, suggesting the inflammasome findings sit within a broader web of metabolic and inflammatory interaction rather than acting in isolation.

Why this matters for MOTS-C research

This study doesn’t overturn or replace the AMPK/metabolic-signaling framework that has driven most MOTS-C research to date — the glucose and CRP results here are broadly consistent with it. What it adds is a specific, testable mechanistic link between MOTS-C and the NLRP3 inflammasome, a pathway implicated in a wide range of chronic inflammatory conditions well beyond diabetes. For researchers whose interest in MOTS-C centers on its metabolic or “exercise-mimetic” properties, this is a data point suggesting the peptide’s downstream effects may extend into cardiac-inflammation biology, an area with its own separate and substantial research literature.

As with any single rodent study, the scope here is specific: a chemically and dietarily induced diabetes model in rats, not a clinical trial, and not evidence about outcomes in humans. The inflammasome-suppression finding is a mechanistic observation worth tracking as the broader mitochondrial-derived-peptide literature develops, rather than a settled conclusion about cardiovascular protection.

Further reading

• Mills, A.R., de Souza, A., Pham, T., Mugisho, O.O. (2026). “Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model.” Experimental Physiology, 111(8), 3742–3752. pubmed.ncbi.nlm.nih.gov/42321010 · doi.org/10.1113/EP093714